169 related articles for article (PubMed ID: 31544207)
1. Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus.
Yen FS; Wang HC; Pan CW; Wei JC; Hsu CC; Hwu CM
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31544207
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes.
Yen FS; Wei JC; Lin MC; Hsu CC; Hwu CM
BMC Endocr Disord; 2021 Feb; 21(1):25. PubMed ID: 33602190
[TBL] [Abstract][Full Text] [Related]
3. All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.
Yen FS; Chiang JH; Hwu CM; Yen YH; Lin BJ; Wei JC; Hsu CC
BMC Endocr Disord; 2019 Jan; 19(1):3. PubMed ID: 30611254
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
[TBL] [Abstract][Full Text] [Related]
5. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
6. Impacts of early insulin treatment vs glimepiride in diabetic patients with background metformin therapy: A nationwide retrospective cohort study.
Yen FS; Hsu CC; Su YC; Wei JC; Hwu CM
Medicine (Baltimore); 2021 Mar; 100(9):e25085. PubMed ID: 33655987
[TBL] [Abstract][Full Text] [Related]
7. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study.
Kuo S; Yang CT; Wu JS; Ou HT
Diabetes Obes Metab; 2019 Feb; 21(2):312-320. PubMed ID: 30187666
[TBL] [Abstract][Full Text] [Related]
8. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
9. A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study.
Yang J; Vallarino C; Bron M; Perez A; Liang H; Joseph G; Yu S
Curr Med Res Opin; 2014 Nov; 30(11):2223-31. PubMed ID: 24983744
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin use on total mortality in patients with type 2 diabetes and chronic obstructive pulmonary disease: A matched-subject design.
Yen FS; Chen W; Wei JC; Hsu CC; Hwu CM
PLoS One; 2018; 13(10):e0204859. PubMed ID: 30286138
[TBL] [Abstract][Full Text] [Related]
12. Decreased incidence of gout in diabetic patients using pioglitazone.
Niu SW; Chang KT; Lin HY; Kuo IC; Chang YH; Chen YH; Hung CC; Chiu YW; Hwang SJ
Rheumatology (Oxford); 2018 Jan; 57(1):92-99. PubMed ID: 29040733
[TBL] [Abstract][Full Text] [Related]
13. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
Anyanwagu U; Mamza J; Donnelly R; Idris I
Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.
Hung YC; Chiu LT; Huang HY; Bau DT
Cardiovasc Diabetol; 2020 Jun; 19(1):94. PubMed ID: 32563247
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan.
Yen FS; Wei JC; Yip HT; Hwu CM; Hou MC; Hsu CC
Hepatol Int; 2021 Feb; 15(1):179-190. PubMed ID: 33423239
[TBL] [Abstract][Full Text] [Related]
16. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin.
Lin HC; Chung CH; Chen LC; Wang JY; Chen CC; Huang KY; Tsai MH; Chien WC; Lin HA
Sci Rep; 2023 Apr; 13(1):6625. PubMed ID: 37095270
[TBL] [Abstract][Full Text] [Related]
18. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study.
Anyanwagu U; Mamza J; Donnelly R; Idris I
Cardiovasc Diabetol; 2017 Aug; 16(1):107. PubMed ID: 28830436
[TBL] [Abstract][Full Text] [Related]
19. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone and oral cancer risk in patients with type 2 diabetes.
Tseng CH
Oral Oncol; 2014 Feb; 50(2):98-103. PubMed ID: 24239280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
